Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to compare, in real life, the risk benefit (including both major
bleeding and thrombotic events (TE) and death from any cause) associated with direct oral
anticoagulants (DOA) and with anti vitamin K (VKA) in older adults (≥ 80 years) suffering
from non valvular atrial fibrillation and living in community or nursing home settings.
An observational multicenter prospective inception cohort will be conducted within the
PRESAGE-Network, an ongoing active network on drug safety in older adults in France involving
a sample of general practitioners (GPs) and pharmacists, for an active surveillance of drug
safety in older adults. GPs and pharmacists will prospectively include all octo+ patients
they care for, newly treated with an oral anticoagulant (VKA or DOA) for nv AF and will
follow them during 2 years at least.
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Acenocoumarol Anticoagulants Apixaban Dabigatran Fluindione Rivaroxaban Vitamin K Vitamins Warfarin